Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

NCT01158885 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Study terminated for lack of accrual.

Conditions

Minimal Residual Disease
Leukemia, Lymphoblastic, Acute
Leukemia, Myelogenous, Acute

Interventions

DRUG: Clofarabine
DRUG: Cytarabine intravenous
DRUG: Methotrexate
DRUG: Intrathecal (IT) Cytarabine

Sponsor

Therapeutic Advances in Childhood Leukemia Consortium

Collaborators

[object Object]